{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:41:19Z","timestamp":1792640479272,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.dmd.2026.100409","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:22:28Z","timestamp":1789665748000},"page":"100409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A practical framework to predict human hepatic clearance for Extended Clearance Classification System class 1B acidic and zwitterionic drugs"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4714-7205","authenticated-orcid":false,"given":"Anna","family":"Vildhede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-1840","authenticated-orcid":false,"given":"Linda C.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7102-9518","authenticated-orcid":false,"given":"P\u00e4r","family":"Nordell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-6018","authenticated-orcid":false,"given":"Kristin","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-4716","authenticated-orcid":false,"given":"Joana","family":"Rebouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0958-0593","authenticated-orcid":false,"given":"Lucas","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6121-7849","authenticated-orcid":false,"given":"Maria","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5126-5733","authenticated-orcid":false,"given":"Marie","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0626-9820","authenticated-orcid":false,"given":"Lloyd","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4708-8797","authenticated-orcid":false,"given":"Bo","family":"Lindmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-1683","authenticated-orcid":false,"given":"Susanne","family":"Winiwarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.dmd.2026.100409_bib1","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1007\/s11095-015-1749-4","article-title":"Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS)","volume":"32","author":"Varma","year":"2015","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.dmd.2026.100409_bib2","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1007\/s11095-016-2024-z","article-title":"Projecting ADME behavior and drug-drug interactions in early discovery and development: application of the Extended Clearance Classification System","volume":"33","author":"El-Kattan","year":"2016","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib3","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.xphs.2017.02.012","article-title":"Comparison of the predictability of human hepatic clearance for organic anion transporting polypeptide substrate drugs between different in vitro-in vivo extrapolation approaches","volume":"106","author":"Izumi","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1124\/jpet.118.252049","article-title":"Organic anion transporter 2-mediated hepatic uptake contributes to the clearance of high-permeability-low-molecular-weight acid and zwitterion drugs: evaluation using 25 drugs","volume":"367","author":"Kimoto","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1208\/s12248-023-00800-x","article-title":"In vitro-in vivo extrapolation and scaling factors for clearance of human and preclinical species with liver microsomes and hepatocytes","volume":"25","author":"Tess","year":"2023","journal-title":"AAPS J"},{"issue":"6","key":"10.1016\/j.dmd.2026.100409_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1124\/dmd.106.014464","article-title":"Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo","volume":"35","author":"Soars","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1124\/dmd.111.042994","article-title":"Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data","volume":"40","author":"Jones","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2013.45","article-title":"ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans","volume":"94","author":"Zamek-Gliszczynski","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib9","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.118.085639","article-title":"A novel unified approach to predict human hepatic clearance for both enzyme- and transporter-mediated mechanisms using suspended human hepatocytes","volume":"47","author":"Riccardi","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/dmd.118.081315","article-title":"Predicting human clearance of organic anion transporting polypeptide substrates using cynomolgus monkey: in vitro-in vivo scaling of hepatic uptake clearance","volume":"46","author":"De Bruyn","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/dmd.118.084194","article-title":"Hepatic organic anion transporting polypeptide-mediated clearance in the beagle dog: assessing in vitro-in vivo relationships and applying cross-species empirical scaling factors to improve prediction of human clearance","volume":"47","author":"Matsunaga","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib12","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1021\/acs.molpharmaceut.6b01059","article-title":"In vitro intrinsic permeability: a transporter-independent measure of Caco-2 cell permeability in drug design and development","volume":"14","author":"Fredlund","year":"2017","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.dmd.2026.100409_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/dmd.120.000131","article-title":"Evaluation of the disconnect between hepatocyte and microsome intrinsic clearance and in vitro in vivo extrapolation performance","volume":"48","author":"Williamson","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100409_bib14","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1021\/acs.molpharmaceut.6b00396","article-title":"Use of H\u03bcREL human coculture system for prediction of intrinsic clearance and metabolite formation for slowly metabolized compounds","volume":"13","author":"Hultman","year":"2016","journal-title":"Mol Pharm"},{"issue":"12","key":"10.1016\/j.dmd.2026.100409_bib15","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1021\/mp400253f","article-title":"Resolving the distribution-metabolism interplay of eight OATP substrates in the standard clearance assay with suspended human cryopreserved hepatocytes","volume":"10","author":"Nordell","year":"2013","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1208\/s12248-017-0051-2","article-title":"Reliable rate measurements for active and passive hepatic uptake using plated human hepatocytes","volume":"19","author":"Bi","year":"2017","journal-title":"AAPS J"},{"issue":"8","key":"10.1016\/j.dmd.2026.100409_bib17","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","article-title":"Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery","volume":"23","author":"Kalvass","year":"2002","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/00498254.2020.1808735","article-title":"Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse","volume":"51","author":"Miyamoto","year":"2021","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/ijms26031141","article-title":"Investigation of biotransformation pathways in a chimeric mouse with a humanized liver","volume":"26","author":"Bonner-Karlsson","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5599\/admet.6.1.470","article-title":"In silico ADME in drug design\u2014enhancing the impact","volume":"6","author":"Winiwarter","year":"2018","journal-title":"ADMET DMPK"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00498254.2012.669080","article-title":"Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes","volume":"42","author":"Sohlenius-Sternbeck","year":"2012","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01062336","article-title":"Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics","volume":"10","author":"Boxenbaum","year":"1982","journal-title":"J Pharmacokinet Biopharm"},{"issue":"20","key":"10.1016\/j.dmd.2026.100409_bib23","doi-asserted-by":"crossref","first-page":"11831","DOI":"10.1021\/acs.jmedchem.0c01033","article-title":"Predicting the human hepatic clearance of acidic and zwitterionic drugs","volume":"63","author":"Tess","year":"2020","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.dmd.2026.100409_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2005.01.018","article-title":"Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics","volume":"77","author":"Niemi","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2008.186","article-title":"Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite","volume":"85","author":"Zheng","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100409_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1208\/s12248-014-9614-7","article-title":"Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide","volume":"16","author":"Varma","year":"2014","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.dmd.2026.100409_bib27","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11095-012-0956-5","article-title":"Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide","volume":"30","author":"Varma","year":"2013","journal-title":"Pharm Res"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/SLC21 family: phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib29","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.112.046193","article-title":"Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes","volume":"40","author":"Menochet","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib30","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/00498254.2018.1512017","article-title":"Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans","volume":"49","author":"Liao","year":"2019","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100409_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42826-019-0032-y","article-title":"Characterization and applications of chimeric mice with humanized livers for preclinical drug development","volume":"36","author":"Tateno","year":"2020","journal-title":"Lab Anim Res"},{"issue":"4","key":"10.1016\/j.dmd.2026.100409_bib33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt.409","article-title":"Ontogeny of hepatic drug transporters as quantified by LC-MS\/MS proteomics","volume":"100","author":"Prasad","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcph.66","article-title":"Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults","volume":"53","author":"Knebel","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib35","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0009-9236(03)00153-X","article-title":"Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia","volume":"74","author":"Hedman","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1007112","article-title":"Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver","volume":"45","author":"Sanoh","year":"2015","journal-title":"Xenobiotica"},{"issue":"12","key":"10.1016\/j.dmd.2026.100409_bib37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1080\/00498254.2016.1265160","article-title":"Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver","volume":"47","author":"Miyamoto","year":"2017","journal-title":"Xenobiotica"},{"issue":"11","key":"10.1016\/j.dmd.2026.100409_bib38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/00498254.2020.1769229","article-title":"Predictability of human pharmacokinetics of drugs that undergo hepatic organic anion transporting polypeptide (OATP)-mediated transport using single-species allometric scaling in chimeric mice with humanized liver: integration with hepatic drug metabolism","volume":"50","author":"Sanoh","year":"2020","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib39","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cts.13070","article-title":"Prediction of human pharmacokinetics for low-clearance compounds using pharmacokinetic data from chimeric mice with humanized livers","volume":"15","author":"Yoshida","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.dmd.2026.100409_bib40","series-title":"ICH M12 guideline on drug interaction studies","year":"2024"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.xphs.2020.10.041","article-title":"Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: comparison with isolated suspended hepatocytes","volume":"110","author":"Yoshikado","year":"2021","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/dmd.118.083733","volume":"47","author":"Kim","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib43","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/dmd.120.000134","article-title":"Effect of human plasma on hepatic uptake of organic anion-transporting polypeptide 1B substrates: studies using transfected cells and primary human hepatocytes","volume":"49","author":"Bi","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.117.077115","article-title":"The phenomenon of albumin-mediated hepatic uptake of organic anion transport polypeptide substrates: prediction of the in vivo uptake clearance from the in vitro uptake by isolated hepatocytes using a facilitated-dissociation model","volume":"46","author":"Miyauchi","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib45","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.xphs.2018.03.012","volume":"107","author":"Poulin","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100409_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107938","article-title":"Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: bridging the gap of hepatic uptake clearance between in vitro and in vivo","volume":"229","author":"Miyauchi","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/03602532.2023.2195133","article-title":"Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review","volume":"55","author":"Schulz","year":"2023","journal-title":"Drug Metab Rev"},{"issue":"6","key":"10.1016\/j.dmd.2026.100409_bib48","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1124\/dmd.124.001645","article-title":"Using the dynamic well-stirred model to extrapolate hepatic clearance of organic anion-transporting polypeptide transporter substrates without assuming albumin-mediated hepatic drug uptake","volume":"52","author":"Yan","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib49","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1124\/dmd.122.000849","article-title":"Is the protein-mediated uptake of drugs by organic anion transporting polypeptides a real phenomenon or an artifact?","volume":"50","author":"Yin","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib50","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/j.1552-4604.1997.tb05629.x","article-title":"Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin","volume":"37","author":"Stern","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"13","key":"10.1016\/j.dmd.2026.100409_bib51","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennernas","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib52","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0009-9236(96)90127-7","article-title":"Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects","volume":"60","author":"Weber","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100409_bib53","first-page":"255","article-title":"Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin","volume":"35","author":"Muck","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-200039020-00002","article-title":"Clinical pharmacokinetics of cerivastatin","volume":"39","author":"Muck","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100409_bib55","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/0049825031000089137","article-title":"Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects","volume":"33","author":"Webber","year":"2003","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100409_bib56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1099-081X(199604)17:3<249::AID-BDD952>3.0.CO;2-E","article-title":"Pharmacokinetics and absolute bioavailability of epristeride in healthy male subjects","volume":"17","author":"Benincosa","year":"1996","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100409_bib57","first-page":"98","article-title":"Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers","volume":"21","author":"Pentikainen","year":"1983","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib58","first-page":"1455","article-title":"[Human pharmacokinetics and metabolism of 14C-labeled gliquidone (AR-DF 26)]","volume":"25","author":"Kopitar","year":"1975","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1016\/j.dmd.2026.100409_bib59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1124\/jpet.120.000457","article-title":"Organic anion-transporting polypeptide 1B1\/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: in vitro-in vivo evaluation in cynomolgus monkey","volume":"377","author":"Eng","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100409_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2710.1995.tb00664.x","article-title":"Comparison of the kinetics of glyburide and its active metabolites in humans","volume":"20","author":"Rydberg","year":"1995","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.dmd.2026.100409_bib61","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/j.1552-4604.1998.tb04809.x","article-title":"Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers","volume":"38","author":"Vachharajani","year":"1998","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100409_bib62","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.118.082966","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 1352 drug compounds","volume":"46","author":"Lombardo","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib63","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40262-015-0365-0","article-title":"Clinical micro-dose studies to explore the human pharmacokinetics of four selective inhibitors of human Nav1.7 voltage-dependent sodium channels","volume":"55","author":"Jones","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmd.2026.100409_bib64","first-page":"636","article-title":"Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers","volume":"36","author":"Hatorp","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100409_bib65","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s002280050667","article-title":"Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing","volume":"55","author":"van Heiningen","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"issue":"12 Pt 1","key":"10.1016\/j.dmd.2026.100409_bib66","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/009127000004001202","article-title":"Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100409_bib67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J Int Med Res"},{"issue":"9","key":"10.1016\/j.dmd.2026.100409_bib68","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0090-9556(24)02974-X","article-title":"Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha\/gamma agonist, after a single oral and intravenous dose in humans","volume":"32","author":"Ericsson","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:18:49Z","timestamp":1792639129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0090955626006781"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100409","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical framework to predict human hepatic clearance for Extended Clearance Classification System class 1B acidic and zwitterionic drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100409"}}